Abd110

Cat. No.:	HY-157767
CAS No.:	3021581-79-0
Molecular Formula:	$C_{41}H_{42}N_8O_7S$
Molecular Weight:	790.89
Target:	ATM/ATR; PROTACs
Pathway:	Cell Cycle/DNA Damage; PI3K/Akt/mTOR; PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Abd110 (compound 42i) is a Lenalidomide-based PROTAC ATR kinase degrader. Abd110 selectively decreases ATR and phospho-ATR without affecting related kinases ATM and DNA-PKcs[1].	
IC_{50} & Target	ATR	Cereblon

In Vitro

Abd110 (compound 42i; 0.5-2 μM; 24 h) selectively degrades ATR through the proteasome, dependent on the E3 ubiquitin ligase component cereblon, and without affecting the associated kinases ATM and DNA-PKcs[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	MIA PaCa-2 cells
Concentration:	0.5 μM, 1 μM, and 2 μM
Incubation Time:	24 h
Result:	Decreased ATR and p-ATR levels without affecting related checkpoint kinases.

REFERENCES

[1]. Abdallah M Alfayomy, et al. Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase. Eur J Med Chem. 2024 Mar 5:267:116167.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA